N-[3-[5-(4-Fluorophenoxy)-furan-2-yl]-2-cyclopenten-1-yl]-N-hydroxyurea | 164340-87-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-[3-[5-(4-Fluorophenoxy)-furan-2-yl]-2-cyclopenten-1-yl]-N-hydroxyurea
• 英文别名: N-[3-[5-(4-Fluorophenoxy)-2-furyl]-2-cyclopenten-1-yl]-N-hydroxyurea；1-[3-[5-(4-Fluorophenoxy)furan-2-yl]cyclopent-2-en-1-yl]-1-hydroxyurea
• CAS: 164340-87-8；164340-88-9；164340-89-0
• 化学式: C₁₆H₁₅FN₂O₄
• 分子量: 318.305
• InChiKey: NPGCXHWYEYZPAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  88.9
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  5-(4-fluorophenoxy)furan-2-carboxaldehyde 生成 N-[3-[5-(4-Fluorophenoxy)-furan-2-yl]-2-cyclopenten-1-yl]-N-hydroxyurea
  参考文献：
  名称：

  Heteroaryl cycloalkenyl hydroxyureas

  摘要：

  具有抑制5-脂氧合酶酶活性的某些新型杂环烷基羟基脲化合物及其药学上可接受的盐，其化学式为（I），其中每个独立的R1是氢、羟基、氯、氟、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基或C1-C4卤代烷氧基；R2是氢或C1-C4烷基；R3是氢、氯、氟或C1-C4烷基；X是O、S、SO或SO2；Z是亚甲基或乙烯基；A是由呋喃、噻吩、吡啶、苯并呋喃、苯并噻吩或喹啉导出的二价基团或这些基团中的一个，其中一个取代基被选择为氯、氟、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基和C1-C4卤代烷氧基之一；n为1、2或3；M是氢或药学上可接受的阳离子。这些化合物在哺乳动物中用于治疗或缓解炎症性疾病、过敏和心血管疾病，并作为制药组合物的活性成分用于治疗这些疾病。

  公开号：

  US05665768A1

文献信息

• HETEROARYL CYCLOALKENYL HYDROXYUREAS
  申请人：PFIZER INC.

  公开号：EP0710233A1

  公开（公告）日：1996-05-08
• US5665768A
  申请人：——

  公开号：US5665768A

  公开（公告）日：1997-09-09
• [EN] HETEROARYL CYCLOALKENYL HYDROXYUREAS<br/>[FR] HETEROARYL CYCLOALCENYL HYDROXIUREES
  申请人：PFIZER INC.

  公开号：WO1995003292A1

  公开（公告）日：1995-02-02

  (EN) Certain novel heteroaryl cycloalkenyl hydroxyurea compounds having the ability to inhibit the 5-lipoxygenase enzyme and having formula (I) and the pharmaceutically acceptable salts thereof, wherein each R1, independently, is hydrogen, hydroxy, chloro, fluoro, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl or C1-C4 haloalkoxy; R2 is hydrogen or C1-C4 alkyl; R3 is hydrogen, chloro, fluoro or C1-C4 alkyl; X is O, S, SO or SO2; Z is methylene or ethylene; A is divalent radical derived from furan, thiophene, pyridine, benzofuran, benzothiophene or quinoline, or one of these groups having one substituent selected from chloro, fluoro, C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl and C1-C4 haloalkoxy; n is 1, 2 or 3; and M is hydrogen or a pharmaceutically acceptable cation. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.(FR) L'invention concerne certains nouveaux composés d'hétéroaryl cycloalcényl hydroxyurées ayant la faculté d'inhiber l'enzyme 5-lypoxygénase, de la formule générale (I) et leurs sels pharmaceutiquement acceptables. Dans cette formule, chaque R1 correspond indépendamment à hydrogène, hydroxy, chloro, fluoro, alkyle C1-C4, alcoxy C1-C4, haloalkyle C1-C4 or haloalcoxy C1-C4; R2 correspond à hydrogène ou alkyle C1-C4; R3 correspond à hydrogène, chloro, fluoro ou alkyle C1-C4; X correspond à O, S, SO ou SO2; Z correspond à méthylène ou ethylène; A correspond à un radical divalent dérivé de furane, thyophène, pyridine, benzofurane, benzothiophène ou quinoline, ou l'un de ces groupes comportant un élément de substitution choisi entre chloro, fluoro, alkyle C1-C4, alcoxy C1-C4, haloalkyle C1-C4 and haloalcoxy C1-C4; n correspond à 1, 2 ou 3; et M correspond à hydrogène ou à un cation pharmaceutiquement acceptable. Ces composés sont utiles pour le traitement ou le soulagement de maladies inflammatoires, d'allergies et de maladies cardio-vasculaires, et comme principe actif dans des compositions pharmaceutiques destinées au traitement de ces états pathologiques.
• Heteroaryl cycloalkenyl hydroxyureas
  申请人：Pfizer Inc.

  公开号：US05665768A1

  公开（公告）日：1997-09-09

  Certain novel heteroaryl cycloalkenyl hydroxyurea compounds having the ability to inhibit the 5-lipoxygenase enzyme and having formula (I) and the pharmaceutically acceptable salts thereof, wherein each R.sup.1, independently, is hydrogen, hydroxy, chloro, fluoro, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkyl or C.sub.1 -C.sub.4 haloalkoxy; R.sup.2 is hydrogen or C.sub.1 -C.sub.4 alkyl; R.sup.3 is hydrogen, chloro, fluoro or C.sub.1 -C.sub.4 alkyl; X is O, S, SO or SO.sub.2 ; Z is methylene or ethylene; A is divalent radical derived from furan, thiophene, pyridine, benzofuran, benzothiophene or quinoline, or one of these groups having one substituent selected from chloro, fluoro, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 haloalkyl and C.sub.1 -C.sub.4 haloalkoxy; n is 1, 2 or 3; and M is hydrogen or a pharmaceutically acceptable cation. These compounds are useful in the treatment or alleviation of inflammatory diseases, allergy and cardiovascular diseases in mammals and as the active ingredient in pharmaceutical compositions for treating such conditions.

  具有抑制5-脂氧合酶酶活性的某些新型杂环烷基羟基脲化合物及其药学上可接受的盐，其化学式为（I），其中每个独立的R1是氢、羟基、氯、氟、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基或C1-C4卤代烷氧基；R2是氢或C1-C4烷基；R3是氢、氯、氟或C1-C4烷基；X是O、S、SO或SO2；Z是亚甲基或乙烯基；A是由呋喃、噻吩、吡啶、苯并呋喃、苯并噻吩或喹啉导出的二价基团或这些基团中的一个，其中一个取代基被选择为氯、氟、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基和C1-C4卤代烷氧基之一；n为1、2或3；M是氢或药学上可接受的阳离子。这些化合物在哺乳动物中用于治疗或缓解炎症性疾病、过敏和心血管疾病，并作为制药组合物的活性成分用于治疗这些疾病。